The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.

Autor: Hickey TE; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Selth LA; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Flinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.; Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia., Chia KM; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Laven-Law G; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Milioli HH; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Roden D; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Jindal S; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Hui M; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Finlay-Schultz J; University of Colorado, Aurora, CO, USA., Ebrahimie E; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Birrell SN; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Stelloo S; Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Radboud University Nijmegen, Nijmegen, the Netherlands., Iggo R; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; Institut Bergonié, University of Bordeaux, Bordeaux, France., Alexandrou S; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Caldon CE; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Abdel-Fatah TM; University of Nottingham, Nottingham, UK., Ellis IO; University of Nottingham, Nottingham, UK., Zwart W; Oncode Institute, Netherlands Cancer Institute, Amsterdam, the Netherlands., Palmieri C; Institute of Systems, Molecular and Integrative Biology, University of Liverpool & Clatterbridge Centre NHS Foundation Trust, Liverpool, UK., Sartorius CA; University of Colorado, Aurora, CO, USA., Swarbrick A; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Lim E; Garvan Institute of Medical Research & St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia., Carroll JS; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Tilley WD; Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia. wayne.tilley@adelaide.edu.au.; Freemason's Foundation Centre for Men's Health, University of Adelaide, Adelaide, South Australia, Australia. wayne.tilley@adelaide.edu.au.

Publikováno v: Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 310-320. Date of Electronic Publication: 2021 Jan 18.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Autor: Abdel-Fatah TM; Clinical Oncology Department, Nottingham University Hospitals, Nottingham, United Kingdom., McArdle SE; John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom., Agarwal D; John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom., Moseley PM; Clinical Oncology Department, Nottingham University Hospitals, Nottingham, United Kingdom., Green AR; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham, United Kingdom., Ball GR; John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom., Pockley AG; John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom., Ellis IO; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham, United Kingdom., Rees RC; John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham, United Kingdom., Chan SY; Clinical Oncology Department, Nottingham University Hospitals, Nottingham, United Kingdom. steve.chan@nuh.nhs.uk.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Feb 15; Vol. 22 (4), pp. 905-14. Date of Electronic Publication: 2015 Aug 03.

SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer.

Autor: Zwart W; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. c.palmieri@liverpool.ac.uk w.zwart@nki.nl., Flach KD; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Rudraraju B; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom., Abdel-Fatah TM; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Gojis O; Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, London, United Kingdom., Canisius S; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Moore D; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom., Nevedomskaya E; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Opdam M; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Droog M; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Chan S; Cancer Research UK Laboratories, Imperial Centre for Translational and Experimental Medicine, Division of Cancer, Imperial College London, London, United Kingdom., Shaw J; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom., Ellis IO; Division of Pathology, School of Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom., Coombes RC; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Carroll JS; Cancer Research UK Cambridge Institute, Cambridge, United Kingdom., Ali S; Clinical Oncology Department, Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom., Palmieri C; Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool, United Kingdom. Liverpool and Merseyside Academic Breast Unit, The Linda McCartney Centre, Royal Liverpool University Hospital, Liverpool, United Kingdom. Academic Department of Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom. c.palmieri@liverpool.ac.uk w.zwart@nki.nl.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Jan 15; Vol. 22 (2), pp. 479-91. Date of Electronic Publication: 2015 Sep 14.

DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.

Autor: Abdel-Fatah TM; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Arora A; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51 PB, UK., Moseley PM; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Perry C; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51 PB, UK., Rakha EA; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK., Green AR; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK., Chan SY; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Ellis IO; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG5 1PB, UK., Madhusudan S; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK.; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG51 PB, UK.

Publikováno v: Oncotarget [Oncotarget] 2015 Sep 08; Vol. 6 (26), pp. 21964-78.

Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer.

Autor: Abdel-Fatah TM; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Middleton FK; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Arora A; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Agarwal D; School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham NG11 8NS, UK., Chen T; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Moseley PM; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Perry C; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Doherty R; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Chan S; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Green AR; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Rakha E; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Ball G; School of Science and Technology, Nottingham Trent University, Clifton Campus, Nottingham NG11 8NS, UK., Ellis IO; Department of Pathology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK., Curtin NJ; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Madhusudan S; Department of Oncology, Nottingham University Hospitals, Nottingham NG5 1PB, UK; Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham University Hospitals, Nottingham NG5 1PB, UK. Electronic address: srinivasan.madhusudan@nottingham.ac.uk.

Publikováno v: Molecular oncology [Mol Oncol] 2015 Mar; Vol. 9 (3), pp. 569-85. Date of Electronic Publication: 2014 Nov 06.